Tucidinostat
- Generic Name
- Tucidinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19FN4O2
- CAS Number
- 1616493-44-7
- Unique Ingredient Identifier
- 87CIC980Y0
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT05519865
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
ChiCGB vs BEAM in High-risk or R/R Lymphomas
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 306
- Registration Number
- NCT05466318
- Locations
- 🇨🇳
Chengdu Third People's Hospital, Chendu, Sichuan, China
🇨🇳People's Hospital of Deyang City, Deyang, Deyang, China
🇨🇳West China Hospital, Sichuan University, Chendu, Sichuan, China
Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Biyun Wang, MD
- Target Recruit Count
- 44
- Registration Number
- NCT05464173
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 70
- Registration Number
- NCT05438706
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 100
- Registration Number
- NCT05411874
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
- Conditions
- Interventions
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- wang shusen
- Target Recruit Count
- 73
- Registration Number
- NCT05411380
- Locations
- 🇨🇳
Shusen Wang, Guangzhou, Gangdong, China
Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- wang shusen
- Target Recruit Count
- 126
- Registration Number
- NCT05390476
- Locations
- 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Guangdong, China
Chidamide Bridging for CAR-T Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05370547
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Hospital, Guangzhou, Guangzhou, China
🇨🇳Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Ge Zheng
- Target Recruit Count
- 31
- Registration Number
- NCT05330364
- Locations
- 🇨🇳
Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing, Jiangsu, China
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05320640
- Locations
- 🇨🇳
Biotherapeutic Department, Chinese PLA General Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.